Osteosarcoma - Pipeline Review, H2 2020

August 2020 | 868 pages | ID: O52BF4A8A59EN
Global Markets Direct

Abstracts

Osteosarcoma - Pipeline Review, H2 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Pipeline Review, H2 2020, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.

Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 28, 14, 3, 29 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 5 and 3 molecules, respectively.

Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Osteosarcoma - Overview
Osteosarcoma - Therapeutics Development
Osteosarcoma - Therapeutics Assessment
Osteosarcoma - Companies Involved in Therapeutics Development
Osteosarcoma - Drug Profiles
Osteosarcoma - Dormant Projects
Osteosarcoma - Discontinued Products
Osteosarcoma - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Osteosarcoma, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Osteosarcoma - Pipeline by Aadi Bioscience Inc, H2 2020
Osteosarcoma - Pipeline by ADCendo ApS, H2 2020
Osteosarcoma - Dormant Projects, H2 2020
Osteosarcoma - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Osteosarcoma, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

Aadi Bioscience Inc
ADCendo ApS
Advanced BioDesign
Advaxis Inc
Advenchen Laboratories LLC
Allosteros Therapeutics Inc
Amgen Inc
AntiCancer Inc
APEIRON Biologics AG
Arrowhead Pharmaceuticals Inc
Ascentage Pharma Group International
Astex Therapeutics Ltd
AstraZeneca Plc
Atlanthera
Aurora BioPharma Inc
Autolus Therapeutics Plc
Bayer AG
BioEclipse Therapeutics Inc
BioMed Valley Discoveries Inc
Boehringer Ingelheim International GmbH
BrightPath Biotherapeutics Co Ltd
Bristol-Myers Squibb Co
Cellectar Biosciences Inc
Cellestia Biotech AG
Cellmid Ltd
CorMedix Inc
CSPC Pharmaceutical Group Ltd
Curamir Therapeutics Inc
Eisai Co Ltd
Eleison Pharmaceuticals LLC
ENB Therapeutics LLC
Endocyte Inc
Epeius Biotechnologies Corp
Exelixis Inc
GlycoMimetics Inc
Hebei Senlang Biotechnology Inc Ltd
HengRui YuanZheng Bio-Technology Co Ltd
ImmunityBio Inc
Intezyne Inc
Iovance Biotherapeutics Inc
Ipsen SA
Isofol Medical AB
Iterion Therapeutics
ITM Isotopen Technologien Munchen AG
Jiangsu Hengrui Medicine Co Ltd
Komipharm International Co Ltd
MacroGenics Inc
Mana Therapeutics Inc
Mateon Therapeutics Inc
MD Biosciences GmbH
MediaPharma SRL
Merck & Co Inc
Merck KGaA
MetCure Therapeutics LLC
Nektar Therapeutics
Nkarta Inc
Novartis AG
Ono Pharmaceutical Co Ltd
PEEL Therapeutics Inc
Pfizer Inc
Pimera Inc
Provectus Biopharmaceuticals Inc
QSAM Therapeutics Inc
Reven Pharmaceuticals Inc
Scancell Holdings Plc
Shionogi & Co Ltd
Singh Biotechnology LLC
Sorrento Therapeutics Inc
Taiho Pharmaceutical Co Ltd
Taithera Inc
Teijin Pharma Ltd
Transtarget Inc
United Therapeutics Corp
Veana Therapeutics LLC
Y-mAbs Therapeutics Inc